Investigators will determine whether N-of-1 trials, as a pragmatic, patient-centered approach
to medication optimization that can overcome key barriers of deprescribing, can lead to
increased subject confidence regarding the decision to continue or discontinue beta-blockers
in older adults with Heart Failure with Preserved Ejection Fraction (HFpEF).